These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 17225280)

  • 41. Long path to approval. A look back at the road to Fuzeon.
    GMHC Treat Issues; 2003 Mar; 17(3):1-5. PubMed ID: 12728856
    [No Abstract]   [Full Text] [Related]  

  • 42. Monitoring the emergence of resistance mutations in patients infected with HIV-1 under salvage therapy with raltegravir in Rio de Janeiro, Brazil: a follow-up study.
    Passaes CP; Guimarães ML; Cardoso SW; Pilotto JH; Veloso V; Grinsztejn B; Morgado MG
    J Med Virol; 2012 Dec; 84(12):1869-75. PubMed ID: 23080489
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Enfuvirtide.
    LaBonte J; Lebbos J; Kirkpatrick P
    Nat Rev Drug Discov; 2003 May; 2(5):345-6. PubMed ID: 12755128
    [No Abstract]   [Full Text] [Related]  

  • 44. HIV fusion inhibitors.
    Pozniak A
    J HIV Ther; 2001 Nov; 6(4):91-4. PubMed ID: 11740409
    [No Abstract]   [Full Text] [Related]  

  • 45. Preventing viral entry. Fusion inhibitors.
    Marks N
    Posit Living; 1999 Mar; 8(2):13. PubMed ID: 12491997
    [No Abstract]   [Full Text] [Related]  

  • 46. First-line use of enfuvirtide-containing HAART regimen with dramatic clinical and immunological improvement in three cases.
    Bourgarit A; Lascoux C; Palmer P; Tuleja E; Pintado C; Farge D; Sereni D
    AIDS; 2006 Feb; 20(3):471-3. PubMed ID: 16439888
    [No Abstract]   [Full Text] [Related]  

  • 47. New class of HIV drugs shows promise.
    Dove A
    Nat Med; 2001 Dec; 7(12):1265. PubMed ID: 11726950
    [No Abstract]   [Full Text] [Related]  

  • 48. [Fusion proteins in HIV-AIDS treatment].
    Hennemann A
    Med Monatsschr Pharm; 2003 Sep; 26(9):300-2. PubMed ID: 14526613
    [No Abstract]   [Full Text] [Related]  

  • 49. New class of medications approved for advance HIV.
    FDA Consum; 2003; 37(3):5. PubMed ID: 12793380
    [No Abstract]   [Full Text] [Related]  

  • 50. HIV-1 coreceptor use in triple-class treatment-experienced patients: baseline prevalence, correlates, and relationship to enfuvirtide response.
    Melby T; Despirito M; Demasi R; Heilek-Snyder G; Greenberg ML; Graham N
    J Infect Dis; 2006 Jul; 194(2):238-46. PubMed ID: 16779731
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry.
    Kilby JM; Hopkins S; Venetta TM; DiMassimo B; Cloud GA; Lee JY; Alldredge L; Hunter E; Lambert D; Bolognesi D; Matthews T; Johnson MR; Nowak MA; Shaw GM; Saag MS
    Nat Med; 1998 Nov; 4(11):1302-7. PubMed ID: 9809555
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.
    Prescrire Int; 2008 Aug; 17(96):135-7. PubMed ID: 19480091
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Enfuvirtide (Fuzeon) for HIV Infection.
    Med Lett Drugs Ther; 2003 Jun; 45(1159):49-50. PubMed ID: 12817195
    [No Abstract]   [Full Text] [Related]  

  • 54. Fresh data on new anti-HIV drugs presented in Durban.
    Leibovich M
    Posit Living; 2000 Aug; 9(7):16-7. PubMed ID: 12492026
    [No Abstract]   [Full Text] [Related]  

  • 55. T-20 (Fuzeon) gets priority review.
    AIDS Treat News; 2002 Oct; (384):4-5. PubMed ID: 12434762
    [No Abstract]   [Full Text] [Related]  

  • 56. Anti-HIV agents. Needle-free T-20.
    TreatmentUpdate; 2005; 17(5):9-10. PubMed ID: 17219660
    [No Abstract]   [Full Text] [Related]  

  • 57. Sustained HIV RNA suppression after switching from enfuvirtide to etravirine in the early access programme.
    Loutfy M; Ribera E; Florence E; De Wit S; Castagna A; Ryan R; Hill A; Vanaken H; van Delft Y; Marks S
    J Antimicrob Chemother; 2009 Dec; 64(6):1341-4. PubMed ID: 19828488
    [No Abstract]   [Full Text] [Related]  

  • 58. Anti-HIV agents. Valproic acid and HIV eradication--many questions remain.
    TreatmentUpdate; 2005; 17(6):5-7. PubMed ID: 17228476
    [No Abstract]   [Full Text] [Related]  

  • 59. The fusion inhibitor enfuvirtide in recent antiretroviral strategies.
    Makinson A; Reynes J
    Curr Opin HIV AIDS; 2009 Mar; 4(2):150-8. PubMed ID: 19339955
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anti-HIV agents. T-20 (enfurvirtide, Fuzeon).
    TreatmentUpdate; 2005; 17(1):5-6. PubMed ID: 17225316
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.